CIRB Studies

Below is the current list of studies covered by the CIRB. Participants should refer to ClinicalTrials.gov for general information about clinical trials. Institutions should refer to the Clinical Trials Support Unit (CTSU) website  for enrollment requirements and accrual status information. 

Study documents approved after July 1, 2013 are available to participating institutions for covered studies on the CTSU website. To request documents approved before July 1, 2013, participating institutions can contact the CIRB Helpdesk.

Review CIRB
Study Number Network Study Title CIRB
EAY191-A6 ECOG-ACRIN A ComboMATCH Treatment Trial: FOLFOX in Combination with Binimetinib as 2nd Line Therapy for Patients with Advanced Biliary Tract Cancers with MAPK Pathway Alterations Adult CIRB - Early Phase Emphasis
EAY191-E4 ECOG-ACRIN A ComboMATCH Treatment Trial ComboMATCH Treatment Trial E4: Nilotinib and Paclitaxel in Patients with Prior Taxane-Treated Solid Tumors Adult CIRB - Early Phase Emphasis
EAY191-E5 ECOG-ACRIN A ComboMATCH Treatment Trial ComboMATCH Treatment Trial E5: A Randomized Phase II Study of AMG 510 (Sotorasib) with or without Panitumumab in Advanced Solid Tumors Adult CIRB - Early Phase Emphasis
EAY191-N2 ECOG-ACRIN A ComboMATCH Treatment Trial EAY191-N2: Phase 2 Trial of Fulvestrant and Binimetinib in Patients with Hormone Receptor-Positive Metastatic Breast Cancer with a Frameshift or Nonsense Mutation or Genomic Deletion in NF1 Adult CIRB - Early Phase Emphasis
EAY191-N4 ECOG-ACRIN Molecular Analysis for Combination Therapy Choice (ComboMATCH) EAY191-N4: A Randomized Trial of Selumetinib and Olaparib or Selumetinib Alone in Patients with Recurrent or Persistent RAS Pathway Mutant Ovarian and Endometrial Cancers A ComboMATCH Treatment Trial Adult CIRB - Early Phase Emphasis
EAY191-N5 ECOG-ACRIN A Randomized Trial of Neratinib, A Pan-ERBB Inhibitor, Alone or in Combination with Palbociclib, a CDK4/6 Inhibitor, in Patients with HER2+ Gynecologic Cancers and Other Solid Tumors: A ComboMATCH Treatment Trial Adult CIRB - Early Phase Emphasis
EAY191-S3 ECOG EAY191-S3, Phase II Study of Paclitaxel (NSC #673089) + Ipatasertib (NSC #781451) in Taxane-Refractory Participants with AKT-Altered Advanced Non-Breast Solid Tumors (A COMBOMATCH Treatment Trial) Adult CIRB - Early Phase Emphasis
EAZ171 ECOG-ACRIN Prospective validation trial of taxane therapy (docetaxel or weekly paclitaxel) and risk of chemotherapy-induced peripheral neuropathy in African American women Cancer Prevention and Control CIRB
GOG-0198 GOG A Randomized Study of Tamoxifen Versus Thalidomide (NSC # 66847) in Patients with Biochemical-Recurrence-Only Epithelial Ovarian Cancer; Cancer of the Fallopian Tube; and Primary Peritoneal Carcinoma after First Line Chemotherapy Adult CIRB - Late Phase Emphasis
GOG-0201 GOG Treatment of Patients with Stage IB2 Carcinoma of the Cervix: A Randomized Comparison of Radical Hysterectomy and Tailored Chemoradiation VERSUS Primary Chemoradiation Adult CIRB - Late Phase Emphasis